With multi-million dollar seed round, AESOMED pioneers recombinant exosome industrialization
Shanghai AESOMED Bioscience Co., Ltd. recently completed a seed funding round raising several million USD. This round saw participation from renowned USD venture capital funds, alongside Web3 fund founders, Hong Kong family offices, and the corporate venture capital (CVC) fund of a listed healthcare company. The capital will be primarily allocated to global market expansion, with the company planning to achieve tens of millions in export revenue and reach breakeven within 18 months.
Founded in August 2023, AESOMED is the world's first biotech company capable of large-scale production of recombinant exosomes. In just two years, the company has achieved a full-chain breakthrough from technology validation to commercial export, establishing itself as a pioneer in the global expansion of Chinese exosome enterprises.
Technical Breakthrough
Exosomes, nanoscale vesicles that facilitate intercellular communication of biological information, demonstrate significant potential in the fields of regenerative medicine and medical aesthetics/anti-aging. The global exosome market is projected to grow from $825 million in 2025 to $2.911 billion by 2030, achieving a compound annual growth rate (CAGR) of 28.7%, with the regenerative aesthetics segment growing even faster at 35.9%.
However, the industrialization of exosomes has consistently faced three major bottlenecks: traditional mesenchymal stem cell extraction methods yield extremely low quantities, producing only microgram levels of exosomes from one liter of culture medium; product purity is generally below 60%, often containing impurities and animal-derived allergenic components, leading to high rates of adverse clinical reactions; and variations in stem cell sources between batches result in significant product inconsistency, making it difficult to meet pharmaceutical-grade quality control standards.
AESOMED's breakthrough lies in its adoption of a recombinant technology pathway based on synthetic biology. The company's self-developed AesoBoost® proprietary technology enables high-efficiency exosome production through precise genetic modification of humanized cell lines that comply with U.S. FDA standards. This technology has secured international PCT patent protection for recombinant exosome production and active ingredient delivery, achieving breakthroughs across multiple dimensions:
Yield Breakthrough: Achieves a high-purity exosome yield exceeding 2.5×10¹³ particles per liter of cell culture medium, representing a more than 100-fold increase over traditional methods, with production costs reduced to 1/50 to 1/100 of conventional approaches.
Purity Breakthrough: Demonstrates an exosome membrane-bound particle ratio exceeding 90%, precisely validated via nano-flow cytometry, significantly surpassing the sub-60% purity levels of traditional methods.
Loading Breakthrough: As the first globally to achieve co-loading of two active proteins both internally and externally on recombinant exosomes, with each exosome carrying over 500 anti-aging proteins at a loading efficiency exceeding 99%.
Quality Control Breakthrough: Utilizes monoclonal technology to ensure high batch-to-batch consistency, with manufacturing processes strictly adhering to biopharmaceutical cGMP standards.
Product Validation
Based on its recombinant exosome technology platform, AESOMED has successfully developed its inaugural product, Formula 313, targeting the medical aesthetics and skincare market for facial skin anti-aging. Results from the company's completed in vitro cell studies and photoaged animal models demonstrate Formula 313's superior performance across multiple key metrics:
Antioxidant Capacity: In both UV radiation-induced and hydrogen peroxide-induced cell damage models, F313 provided significantly greater protection to damaged cells compared to traditional mesenchymal stem cell-derived exosomes, substantially reducing intracellular ROS release.
Anti-Aging Efficacy: In photoaged animal models, F313 treatment markedly improved UV-induced skin photoaging in rats, showing visibly reduced wrinkles from day 22 onward, with effects surpassing those of hyaluronic acid and retinoic acid.
Collagen Regeneration: Both collagen mRNA and protein levels were significantly elevated, accompanied by restoration of dermal fiber structure.
Anti-Inflammatory Action: F313 reduced ROS levels and downregulated inflammatory factors including IL-1β, IL-6, and TNF-α, alleviating epidermal damage and inflammatory infiltration.
Safety Profile: No adverse reactions were observed throughout the studies, indicating favorable biosafety characteristics.
AESOMED plans to complete a human efficacy clinical trial involving no fewer than 100 subjects by 2026, with subsequent publication of scientific papers. The research will cover the treatment of stubborn skin conditions including melasma and rosacea, as well as combination therapies with aesthetic medical devices such as golden microneedling.
The company has established deep collaborations with several leading research institutions, including the team of Professor Yang Zhaogang at Jilin University's School of Life Sciences, Shanghai Dermatology Hospital, Shanghai Changzheng Hospital, and Kaohsiung Medical University Hospital in Taiwan. Related scientific achievements are slated for publication in a top-tier global journal of regenerative medicine materials.
Commercial Breakthrough
AESOMED has demonstrated remarkable velocity in its commercialization journey. Established in August 2023, the company completed technological validation for recombinant exosomes in February 2024, conducted photoaging animal studies by March 2025, and filed an international PCT patent application.
Within a concentrated six-month period from May to October 2025, the company achieved several major commercial milestones. It secured the world's first INCI name for recombinant exosomes, enabling its products to be used as cosmetic ingredients in compliant global markets. AESOMED fulfilled the first export order for Chinese recombinant exosomes, breaking the deadlock in international expansion for domestic exosome enterprises and achieving the largest single export order by a Chinese exosome company. Concurrently, product commercialization has commenced in markets including Taiwan, China, and South Korea.
Regarding production capacity, AESOMED has established biopharmaceutical cGMP-compliant manufacturing capabilities, achieving single-batch exosome production exceeding 100 liters at the trillion-particle scale, with maximum single-batch capacity reaching 1,000 liters. This production scale ranks among the highest within China's exosome sector.
Market Strategy
AESOMED's strategic decision to prioritize overseas markets as its primary breakthrough is grounded in a thorough analysis of the global exosome regulatory landscape:
In November 2023, South Korea's Ministry of Food and Drug Safety (MFDS) updated its Cosmetic Safety Standards Regulations, incorporating safety standards for human cell and tissue culture media as cosmetic ingredients. South Korea is a leading market for exosome R&D and application, as well as a major exporter of K-Beauty products.
On March 21, 2024, the Taiwan Food and Drug Administration issued the Requirements for Submitting Documentation for Case-by-Case Review of Human Cell-Derived Exosomes in Cosmetics, which took effect immediately. This marked Asia's first systematic regulatory framework specifically for exosome cosmetics . AESOMED has already secured substantial export orders in this market .
As of February 2025, 24 exosome-related INCI names had been registered in the International Nomenclature of Cosmetic Ingredients (INCI) database maintained by the U.S. Personal Care Products Council (PCPC). Having secured INCI certification for its recombinant exosomes, AESOMED plans to collaborate with cosmetic CDMO companies possessing FDA filing credentials for brand promotion.
The Southeast Asian market similarly benefits from the ASEAN Cosmetic Directive framework, which provides clear regulatory requirements and supports rapid market growth.
In June 2025, China's Center for Drug Evaluation (CDE) issued the "Scope, Classification, and Interpretation of Advanced Therapy Medicinal Products (ATMP) (Draft for Comment)," which for the first time clarified the regulatory pathway for "exosomes as innovative biological drugs." AESOMED is actively communicating with the National Medical Products Administration (NMPA) and the National Institutes for Food and Drug Control (NIFDC) and plans to submit an Investigational New Drug (IND) application in 2026.
This funding round will be primarily allocated to overseas market expansion. In 2026, AESOMED plans to present at global premier anti-aging conferences such as AMWC and IMCAS, with the goal of establishing distribution channels in key markets including South Korea, Taiwan (China), Southeast Asia, and the Middle East within 12 months, and achieving tens of millions in export revenue and company-wide profitability within 18 months.
Competitive Advantage
A competitive landscape is taking shape in the global exosome market. South Korea's ExoCoBio currently stands as the market leader, having raised a cumulative $56.3 million with a valuation exceeding $800 million in 2025 and annual revenue approaching $100 million. The company is the first in South Korea to obtain three types of GMP certifications, and its ASCE brand has achieved commercialization in its domestic market, the United States, and Europe.
In the U.S. market, NASDAQ-listed Capricor Therapeutics entered a distribution agreement with Japanese pharmaceutical giant Nippon Shinyaku, with potential milestone payments totaling up to $1.5 billion. Direct Biologics' ExoFlo has advanced into the most advanced Phase III clinical trial for exosome therapies globally.
Compared to international competitors, AESOMED's differentiated advantage lies in its recombinant technology platform. The company possesses first-mover advantages across multiple dimensions including technological pathways, intellectual property, and production capacity, positioning it to potentially attain a leadership position in China's exosome market and compete internationally with established players like ExoCoBio.
Industry Outlook
The exosome industry stands at a critical inflection point poised for industrial expansion. The annual volume of scientific publications has surged from just 2 in 1994 to over 5,000 by 2024, with more than 150 clinical trials underway globally. The 2013 Nobel Prize awarded for research on vesicle transport mechanisms signifies exosomes' transition from fundamental research into clinical translation and commercial application.
However, traditional mesenchymal stem cell extraction methods are inadequate to support large-scale industrialization. AESOMED's recombinant exosome technology offers the industry a new developmental pathway. Just as insulin production evolved from animal pancreas extraction to genetic recombination, and hyaluronic acid and collagen advanced from animal tissue extraction to microbial fermentation, exosomes are inevitably progressing from stem cell extraction to recombinant production. Recombinant technology represents superior production efficiency, enhanced quality control, reduced manufacturing costs, and improved product safety.
As a platform technology, recombinant exosomes possess remarkable extensibility. AESOMED has developed a pipeline of investigational products loaded with various active ingredients, targeting several multi-billion-dollar health markets including hair regeneration and ophthalmic diseases. Leveraging its core technology, the company has also created investigational products targeting endogenous anti-aging and longevity medicine, which have undergone preliminary cellular and animal testing and show potential to become next-generation alternatives to NMN and NAD+.
The company plans to initiate its Series A financing round in December to accelerate the global expansion of its recombinant exosome technology and advance investigational new drug applications.